Innovative approach using mouse models to study human autoimmune diseases like SLE, focusing on organ-specific manifestations and response to CAR T and BITE therapies. Technologies include flow cytometry and confocal microscopy for detailed analysis.
This research focuses on assessing autoreactive manifestations in lupus mouse models to mimic human autoimmune diseases such as Systemic Lupus Erythematosus (SLE). By employing spontaneous mouse models, the study aims to reflect relevant disease presentations and evaluate responses to bispecific or engager therapies like CAR T cells and BITEs (bispecific T-cell engagers). The research utilizes advanced technologies to provide insights into organ-specific manifestations and potential therapeutic responses.
The research is at Technology Readiness Level 5, indicating that it is at the validation stage in a relevant environment. Current studies include evaluating the efficacy of molecular bivalent engagers (BITEs) and CAR T cell therapies in mouse models, with plans to further develop the interface between molecular and cellular mechanisms in autoimmunity.
The University of Tennessee Health Science Center is a public academic health sciences institution headquartered in Memphis, serving the state through comprehensive colleges in the health professions and a statewide network of clinical education sites. Industry collaborates through integrated partnerships with teaching hospitals across Memphis, Chattanooga, Knoxville, and Nashville, providing access to diverse patient populations, real-world data, and clinician investigators for sponsored studies and translation. Shared core facilities, biobanking capabilities, and translational research spaces—along with simulation and surgical training environments—support contract research, prototyping and validation, and multicenter trials coordination. Research is supported by competitive federal funding led by the NIH, with additional awards from other national agencies. A dedicated technology transfer office manages IP, licensing, sponsored-research agreements, and startup support to accelerate commercialization.